Nektar Therapeutics (NKTR)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 906709 · fiscal year ends in Dec
Closing price $39.23 on 29 Oct 2026; 52-week range $35.12 to $100.35.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $54.6M
- Revenue growth
- -27.2%
- Net income, last twelve months
- -$157.1M
- Earnings per share
- -$6.70
- Operating margin
- -257.8%
- Net margin
- -287.8%
- Free cash flow
- -$234.0M
- Return on equity
- -17.4%
- Market value
- $799.5M
- Cash
- $39.3M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 20.4M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $55.2M | -$140.1M | -$164.1M | -$9.73 | -$208.7M | 10-K filed 13 Mar 2026 |
| FY2024 | 31 Dec 2024 | $98.4M | -$105.2M | -$119.0M | -$8.70 | -$177.2M | 10-K filed 14 Mar 2025 |
| FY2023 | 31 Dec 2023 | $90.1M | -$263.7M | -$276.1M | -$21.75 | -$193.5M | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $92.1M | -$376.2M | -$368.2M | -$29.55 | -$309.7M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $101.9M | -$446.1M | -$523.8M | -$42.90 | -$427.6M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $10.1M | -$40.6M | -$1.23 |
| Q1 FY2026 | 31 Mar 2026 | $10.9M | -$44.9M | -$1.82 |
| Q4 FY2025 | 31 Dec 2025 | $21.8M | -$36.1M | -$1.78 |
| Q3 FY2025 | 30 Sep 2025 | $11.8M | -$35.5M | -$1.87 |
| Q2 FY2025 | 30 Jun 2025 | $11.2M | -$41.6M | -$2.95 |
| Q1 FY2025 | 31 Mar 2025 | $10.5M | -$50.9M | -$3.60 |
| Q4 FY2024 | 31 Dec 2024 | $29.2M | $7.3M | $0.45 |
| Q3 FY2024 | 30 Sep 2024 | $24.1M | -$37.1M | -$2.70 |
Company events
The newest 8-K filings of 321 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 1 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 25 Sep 2026 | 8-K | Other events | 8.01 |
| 8 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 8 May 2026 | 8-K | Leadership change, Material agreement | 1.01, 5.02, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Apr 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 20 Apr 2026 | 8-K | Investor update | 7.01 |
| 20 Apr 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 12 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Feb 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 680 held.
| Filed | Form | Period |
|---|---|---|
| 20 Oct 2026 | S-8 | – |
| 1 Oct 2026 | 8-K | 1 Oct 2026 |
| 25 Sep 2026 | 8-K | 24 Sep 2026 |
| 8 Sep 2026 | 8-K | 8 Sep 2026 |
| 14 Aug 2026 | S-8 | – |
| 14 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 5 Jun 2026 | 8-K | 5 Jun 2026 |
| 8 May 2026 | 8-K | 8 May 2026 |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 24 Apr 2026 | ARS | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 18 Aug 2026 | Zalevsky Jonathan, Chief R&D Officer | Sale outside a trading plan | 186 | $71.98 | $13.4K | 9,570 | 20 Aug 2026 |
| 18 Aug 2026 | Robin Howard W, President & CEO | Sale outside a trading plan | 418 | $71.98 | $30.1K | 54,627 | 20 Aug 2026 |
| 30 Jun 2026 | Zalevsky Jonathan, Chief R&D Officer | Sale under a trading plan | 5,681 | $70.00 | $397.7K | 9,756 | 2 Jul 2026 |
| 17 Jun 2026 | Robin Howard W, President & CEO | Sale under a trading plan | 5,500 | $60.81 | $334.5K | 59,545 | 18 Jun 2026 |
| 17 Jun 2026 | Robin Howard W, President & CEO | Sale under a trading plan | 4,500 | $61.65 | $277.4K | 55,045 | 18 Jun 2026 |
| 16 Jun 2026 | Robin Howard W, President & CEO | Sale under a trading plan | 5,303 | $59.97 | $318.0K | 69,742 | 18 Jun 2026 |
| 16 Jun 2026 | Robin Howard W, President & CEO | Sale under a trading plan | 4,697 | $60.71 | $285.2K | 65,045 | 18 Jun 2026 |
| 15 Jun 2026 | Zalevsky Jonathan, Chief R&D Officer | Sale under a trading plan | 5,538 | $60.71 | $336.2K | 15,437 | 17 Jun 2026 |
| 19 May 2026 | Zalevsky Jonathan, Chief R&D Officer | Sale outside a trading plan | 199 | $65.51 | $13.0K | 20,975 | 21 May 2026 |
| 19 May 2026 | Robin Howard W, President & CEO | Sale outside a trading plan | 444 | $65.51 | $29.1K | 75,045 | 21 May 2026 |
| 18 Feb 2026 | Zalevsky Jonathan, Chief R&D Officer | Sale outside a trading plan | 180 | $73.00 | $13.1K | 21,174 | 20 Feb 2026 |
| 18 Feb 2026 | Robin Howard W, President & CEO | Sale outside a trading plan | 423 | $73.00 | $30.9K | 75,489 | 20 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 18 Aug 2026 | Zalevsky Jonathan, Officer | 186 | $13.4K | 18 Aug 2026 |
| 18 Aug 2026 | ROBIN HOWARD W, Officer, Director | 418 | $30.1K | 18 Aug 2026 |
| 30 Jun 2026 | JONATHAN ZALEVSKY, Officer | 5,681 | $371.5K | 30 Jun 2026 |
| 17 Jun 2026 | ROBIN HOWARD W, Officer, Director | 10,000 | $602.7K | 17 Jun 2026 |
| 16 Jun 2026 | ROBIN HOWARD W, Officer, Director | 10,000 | $609.6K | 16 Jun 2026 |
| 15 Jun 2026 | JONATHAN ZALEVSKY, Officer | 5,538 | $328.8K | 15 Jun 2026 |
| 19 May 2026 | Zalevsky Jonathan, Officer | 199 | $13.0K | 19 May 2026 |
| 19 May 2026 | ROBIN HOWARD W, Officer, Director | 444 | $29.1K | 19 May 2026 |
| 13 Mar 2026 | Wilson Mark Andrew, Former Officer | 78,510 | $5.7M | 13 Mar 2026 |
| 18 Feb 2026 | Zalevsky Jonathan, Officer | 180 | $13.1K | 18 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 28 Sep 2026 | Two Seas Capital LP | 13G amended | 9.8% | 3.3M |
| 14 Aug 2026 | Two Seas Capital LP | 13G amended | 9.1% | 3.1M |
| 14 Aug 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G amended | 7.1% | 2.4M |
| 31 Jul 2026 | Vanguard Capital Management | 13G | 5.17% | 1.7M |
| 29 Jul 2026 | BlackRock, Inc. | 13G | 7.8% | 2.6M |
| 15 May 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G amended | 9.8% | 2.9M |
| 6 May 2026 | FMR LLC | 13G amended | 15% | 4.3M |
| 17 Apr 2026 | Two Seas Capital LP | 13G | 6.8% | 2.0M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 6 Mar 2026 | FMR LLC | 13G | 11.1% | 3.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 7.0M | +0.42% | 3.52 |
| 30 Sep 2026 | 7.0M | +21.49% | 3.76 |
| 15 Sep 2026 | 5.7M | -5.48% | 7.57 |
| 31 Aug 2026 | 6.1M | -1.63% | 11.45 |
| 14 Aug 2026 | 6.2M | -2.12% | 10.43 |
| 31 Jul 2026 | 6.3M | -7.57% | 8.62 |
| 15 Jul 2026 | 6.8M | -1.12% | 6.97 |
| 30 Jun 2026 | 6.9M | +39.48% | 4.47 |
Funds that hold it
From each fund's latest Form 13F.
282 funds held it at 30 Jun 2026: 167 added and 41 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 5,067,920 | $353.8M | +764,732 |
| Two Seas Capital LP | 3,092,234 | $215.9M | +1,133,056 |
| BlackRock, Inc. | 2,941,851 | $205.4M | +2,249,201 |
| BVF Inc. | 2,391,075 | $166.9M | -168,520 |
| Vanguard Capital Management LLC | 1,496,849 | $104.5M | +299,794 |
| Two Sigma Investments, LP | 1,202,004 | $83.9M | +271,263 |
| Vestal Point Capital, LP | 1,000,000 | $69.8M | +715,000 |
| Morgan Stanley | 936,560 | $65.4M | +277,173 |
| State Street Corp. | 909,679 | $63.5M | +664,952 |
| Geode Capital Management, LLC | 881,306 | $61.5M | +534,511 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B